

# Real-World Utilization of Fetal Bovine Dermis: A Clinician-Reported Snapshot

Yifei Dai, PhD; Maria Leonard, BSN RN; Malachy Asuku, MD;  
Angela Siebeneck, MSN RN; Yi Arnold, PhD; Paula Searcy MBA


Integra LifeSciences Corp., Plainsboro, NJ

## INTRODUCTION

- Complex wounds, acute or chronic, often involve tissue loss, exposed structures, and compromised vascularity, which can impede closure.
- Advanced biologic scaffolds, such as fetal bovine dermis (FBD), provide structural integrity and support tissue regeneration.
- FBD effectiveness has been documented across various wound indications.<sup>1-8</sup>
- However, real-world insights into broad utilization across diverse specialties and wound types remain limited.
- This analysis provides a snapshot of FBD use and outcomes in routine clinical practice in US and EU.

## OBJECTIVE

To describe real-world clinical utilization patterns, closure outcomes, and safety experience with fetal bovine dermis across diverse wound types and surgical specialties




**Figure 1.** PriMatrix Dermal Scaffold (Integra LifeSciences, Plainsboro, NJ)

## RESULTS

A total of 985 real-world cases were submitted by 117 clinicians


- Clinician experience: median 15.9 years (range 3-35)
- FBD use spanned:
  - chronic ulcers
  - surgical wounds
  - trauma wounds
  - complex wound presentations (tunneling/undermining and persistent draining).

### FBD used across a broad range of clinical specialties




**Figure 2.** Clinical specialty distribution among the submitting clinicians.

### Majority of wounds closed by 12 weeks



**Figure 3.** Wound closure status at 12 weeks.

### Minimal adverse events reported across the cohort



**Figure 4.** Safety results.

## METHODS

- A retrospective chart review was performed using a HIPAA-compliant digital platform that enabled secure abstraction of real-world clinical data.
- Licensed clinicians from US and EU submitted de-identified cases treated with the FBD device between June 2022 and June 2025. Each contributor could enter up to 20 cases.
- Structured forms were used to capture:
  - Clinical specialty
  - Wound type and indication
  - Outcomes: 12-week closure status and adverse events
- Descriptive analysis were performed on the dataset.
- The study was exempt from IRB/consent requirements due to its retrospective, anonymized design.

## DISCUSSION

- This multinational review shows broad real-world adoption of FBD across wound types and surgical specialties.
- High closure rates and minimal device-related AEs reinforce FBD's role as a versatile scaffold for complex wound management.
- The retrospective, clinician-abstracted nature of the dataset presents inherent limitations, but the scope and consistency of outcomes support relevance to everyday practice.

## CONCLUSION

- FBD demonstrated high real-world healing rates, broad utility, and a favorable safety profile across diverse complex wounds.
- These findings support its use as a practical and reliable option in multidisciplinary wound management, with future studies needed to further refine utilization patterns.

### References:

[1] Kavros SJ. *Foot Ankle Spec.* 5: 230-234, 2012  
 [2] Kavros SJ. *Adv Skin Wound Care.* August 2014  
 [3] Karr J. *Adv Skin Wound Care.* 21: 270-4, 2011  
 [4] Lullove EJ. *J Am Podiatr Med Assoc.* 102: 233-239, 2012

[5] Strauss NH. *Wounds.* 24: 327-334, 2012  
 [6] Neill J. *Ann Plast Surg.* 68: 451-456, 2012  
 [7] Hayn E. *Int Wound J.* 2014;11(6):675-680  
 [8] Lantis JC. *J Wound Care.* 2021;30(sup7):S18-S27